ZYME
Document Zymeworks Reports 2021 Third Quarter Financial Results
Wednesday, November 3, 2021 BiopharmaWatch Research 1 min read Key Takeaway: q3_2021xpressxre.htm EX-99.1 Document Zymeworks Reports 2021 Third Quarter Financial Results
Price reaction · baseline $24.1 (2021-11-02 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers
Full Press Release Details
q3_2021xpressxre.htm EX-99.1 Document Zymeworks Reports 2021 Third Quarter Financial Results.